Table 1.
Demographic and clinical characteristics of the whole cohort of patients.
|
Drug
N (%) |
FTY
68 (26.2) |
RTX/OCRE
65 (25) |
DMF
37 (14.2) |
CLD
29 (11.2) |
TFM
23 (8.8) |
IFN/GA
20 (7.7) |
ALM
18 (6.9) |
ANOVA Test after Bonferroni Correction p-Value |
|---|---|---|---|---|---|---|---|---|
| Age (mean ± SD) | 44.6 ± 9.8 | 44.8 ± 12.5 | 44.6 ± 11.7 | 36.9 ± 9.6 | 44.7 ± 11.1 | 39.2 ± 11 | 38.8 ± 10 | CLD vs FTY = 0.03 CLD vs RTX/OCRE = 0.03 |
| Female (%) |
43 (63.2) |
39 (60) |
24 (64.9) |
24 (82.7) |
14 (60.9) |
15 (75) |
11 (61.1) |
CLD vs RTX/OCRE = 0.01 CLD vs TFM = 0.03 CLD vs ALM = 0.03 CLD vs FTY = 0.04 |
| Disease duration* (mean ± SD) | 17.9 ± 7.8 | 10 ± 7.6 | 10.1 ± 7.6 | 9.3 ± 6.2 | 12.1 ± 8.4 | 7.9 ± 6.7 | 15.3 ± 5.9 | FTY vs IFN/GA = 0.001 FTY vs CLD = 0.01 FTY vs RTX/OCRE = 0.02 |
| Patients with previous use of IM (%) |
21 (30.9%) | 10 (15.6%) | 5 (13.5%) | 4 (13.8%) | 5 (21.7%) | 0 | 5 (27.8%) | FTY vs CLD = 0.01 FTY vs DMF = 0.01 FTY vs RTX/OCRE = 0.03 |
| Patients with previous use of NTZ (%) |
41 (60.3%) | 19 (29.2%) | 7 (18.9%) | 10 (34.5%) | 2 (8.7%) | 0 | 13 (72.2%) | TFM vs ALM = 0.001 TFM vs FTY = 0.01 TFM vs CLD = 0.02 TFM vs RTX/OCRE = 0.03 |
| EDSS at T0 (mean ± SD) |
3.3 ± 2.1 | 4.0 ± 2.1 | 3.0 ± 1.9 | 2.7 ± 1.7 | 2.5 ± 2.1 | 2.0 ± 1.4 | 3.5 ± 1.8 | IFN/CA vs RTX/OCRE = 0.001 |
| EDSS at T1 (mean ± SD) |
3.7 ± 2.4 | 3.8 ± 2.5 | 3.2 ± 2.2 | 2.6 ± 1.9 | 3.1 ± 2.6 | 2.2 ± 1.7 | 3.4 ± 2.1 | n.s. |
| DMT duration** (mean ± SD) |
48.6 ± 23.6 | 25.9 ± 15.0 | 36.9 ± 21.3 | 18.7 ± 7.4 | 22.3 ± 9.5 | 28.8 ± 13.4 | 43.7 ± 14.5 | FTY vs CLD = 0.001 FTY vs RTX/OCRE = 0.001 FTY vs IFN/GA = 0.001 FTY vs TFM = 0.03 DMF vs CLD = 0.001 |
| Time between T0-T1 (mean ± SD)** |
26.2 ± 16.5 | 21.8 ± 14.0 | 25.7 ± 15.7 | 15.3 ± 7.3 | 17.9 ± 9.1 | 26 ± 13.7 | 30.1 ± 17.7 | ALM vs CLD = 0.0001 ALM vs TFM = 0.0001 FTY vs CLD = 0.001 FTY vs TFM = 0.001 IFN/GA vs CLD = 0.01 |
Note: *in years
**in months
Abbreviations: DMT: disease-modifying therapy; FTY; fingolimod; RTX/OCRE: rituximab or ocrelizumab; DMF: dimethyl-fumarate; CLD: cladribine; TFM: teriflunomide; IFN/GA: interferons or glatiramer acetate; ALM: alemtuzumab; IM: immunosuppressant drugs; EDSS: Expanded disability status scale; SD: standard deviation; n.s.: not significant.